|
HER2 re-evaluation by serum HER2, CTC, and metastatic tissue |
||||
| Primary tissue |
||||
|
|
||||
| HER2 evaluation |
Total |
HER2 negative |
HER2 unknown |
HER2 positive |
|
|
||||
| Serum HER2 (n = 77) |
77 |
53 |
19 |
5 |
| HER2 negative |
57 |
41 (77) |
15 (79) |
1 (20) |
| HER2 positive |
20 |
12 (23) |
4 (21) |
4 (80) |
| CTC HER2 (n = 21)a |
21 |
12 |
6 |
3 |
| HER2 negative |
13 |
8 (67) |
3 (50) |
2 (67) |
| HER2 positive |
8 |
4 (33) |
3 (50) |
1 (33) |
| Metastatic tissue (n = 10)b |
10 |
8 |
2 |
- |
| HER2 negative |
8 |
6 (75) |
2 (100) |
- |
| HER2 positive |
2 |
2 (25) |
0 |
- |
|
1Fifty-six patients were circulating tumor cell (CTC) negative; in 10 patients no CTC evaluation could be performed. bMetastatic tissue was only available in 10 patients. HER, human epidermal growth factor receptor. | ||||
Fehm et al. Breast Cancer Research 2007 9:R74 doi:10.1186/bcr1783 |
||||